Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.93
NAS:ARRY's Cash to Debt is ranked lower than
82% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. NAS:ARRY: 0.93 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ARRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.72 Max: No Debt
Current: 0.93
Equity to Asset -0.31
NAS:ARRY's Equity to Asset is ranked lower than
95% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ARRY: -0.31 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ARRY' s Equity to Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.23 Max: 0.93
Current: -0.31
-1.55
0.93
F-Score: 3
Z-Score: -3.30
M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -54.57
NAS:ARRY's Operating margin (%) is ranked higher than
55% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. NAS:ARRY: -54.57 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ARRY' s Operating margin (%) Range Over the Past 10 Years
Min: -410.11  Med: -89.25 Max: 3.18
Current: -54.57
-410.11
3.18
Net-margin (%) -62.42
NAS:ARRY's Net-margin (%) is ranked higher than
52% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:ARRY: -62.42 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ARRY' s Net-margin (%) Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: -62.42
-511.63
18.05
ROA (%) -54.68
NAS:ARRY's ROA (%) is ranked lower than
71% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. NAS:ARRY: -54.68 )
Ranked among companies with meaningful ROA (%) only.
NAS:ARRY' s ROA (%) Range Over the Past 10 Years
Min: -99.03  Med: -50.67 Max: 5.56
Current: -54.68
-99.03
5.56
ROC (Joel Greenblatt) (%) -740.44
NAS:ARRY's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. NAS:ARRY: -740.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ARRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1397.54  Med: -273.72 Max: 297.05
Current: -740.44
-1397.54
297.05
Revenue Growth (3Y)(%) 14.30
NAS:ARRY's Revenue Growth (3Y)(%) is ranked higher than
66% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:ARRY: 14.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ARRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.9  Med: -2.7 Max: 39.8
Current: 14.3
-35.9
39.8
EBITDA Growth (3Y)(%) 9.40
NAS:ARRY's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:ARRY: 9.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ARRY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.3  Med: 0.7 Max: 105.1
Current: 9.4
-66.3
105.1
EPS Growth (3Y)(%) 4.50
NAS:ARRY's EPS Growth (3Y)(%) is ranked higher than
61% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NAS:ARRY: 4.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ARRY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.4  Med: 0.8 Max: 55.7
Current: 4.5
-50.4
55.7
» NAS:ARRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ARRY Guru Trades in Q4 2015

Steven Cohen 952,200 sh (New)
Paul Tudor Jones 107,347 sh (+833.45%)
Jim Simons 3,210,394 sh (+245.42%)
Ken Fisher 135,695 sh (unchged)
» More
Q1 2016

ARRY Guru Trades in Q1 2016

Ken Fisher 135,695 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 2,154,652 sh (-32.89%)
» More
Q2 2016

ARRY Guru Trades in Q2 2016

Ken Fisher 135,695 sh (unchged)
Jim Simons 17,452 sh (-99.19%)
» More
Q3 2016

ARRY Guru Trades in Q3 2016

Joel Greenblatt 16,705 sh (New)
Paul Tudor Jones 135,000 sh (New)
Jim Simons 424,452 sh (+2332.11%)
Ken Fisher 135,895 sh (+0.15%)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:OPHT, NYSE:AXON, NAS:ALDR, NAS:FOLD, NAS:XLRN, OTCPK:GENSF, NAS:CLVS, NAS:AAAP, NAS:CHRS, NYSE:EBS, NAS:FGEN, OTCPK:MPSYY, NAS:DERM, OTCPK:SXMDF, NAS:AMAG, NAS:TBPH, NAS:RGEN, NAS:INVA, NAS:XNCR, NYSE:CBM » details
Traded in other countries:AR2.Germany,
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/S 7.32
ARRY's P/S is ranked higher than
60% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. ARRY: 7.32 )
Ranked among companies with meaningful P/S only.
ARRY' s P/S Range Over the Past 10 Years
Min: 1.43  Med: 6.92 Max: 24.26
Current: 7.32
1.43
24.26
Current Ratio 2.46
ARRY's Current Ratio is ranked lower than
69% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ARRY: 2.46 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.93 Max: 7.86
Current: 2.46
0.81
7.86
Quick Ratio 2.46
ARRY's Quick Ratio is ranked lower than
65% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. ARRY: 2.46 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.93 Max: 7.55
Current: 2.46
0.81
7.55
Days Sales Outstanding 76.96
ARRY's Days Sales Outstanding is ranked lower than
62% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. ARRY: 76.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 47.09 Max: 497.21
Current: 76.96
2.06
497.21
Days Payable 83.77
ARRY's Days Payable is ranked higher than
64% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ARRY: 83.77 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 83.77
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ARRY: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.8 Max: -4.2
Current: -7.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.07
ARRY's Price/Median PS Value is ranked lower than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ARRY: 1.07 )
Ranked among companies with meaningful Price/Median PS Value only.
ARRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.91 Max: 3.19
Current: 1.07
0.21
3.19
Earnings Yield (Greenblatt) (%) -6.40
ARRY's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. ARRY: -6.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6.4  Med: 2.25 Max: 5.1
Current: -6.4
-6.4
5.1

More Statistics

Revenue (TTM) (Mil) $161.0
EPS (TTM) $ -0.71
Beta1.24
Short Percentage of Float14.79%
52-Week Range $2.39 - 8.27
Shares Outstanding (Mil)168.55
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference Nov 22 2016
Is Redmile Group Right to Bet on Array Biopharma Inc (ARRY), Amicus Therapeutics, Inc. (FOLD) & Two... Nov 15 2016
Array Biopharma Inc (ARRY) Updates On COLUMBUS Phase 3 And It’s Impressive Nov 10 2016
Array Biopharma Inc (ARRY) Stock: Gaining Big On Clinical Data Nov 10 2016
ARRAY BIOPHARMA INC Financials Nov 09 2016
The Market Offers Some Opportunities but They're Disappearing Fast Nov 09 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 09 2016
COLUMBUS Phase 3 Study Results in BRAF-Mutant Melanoma Presented at Society for Melanoma Research... Nov 09 2016
Array BioPharma To Present At The Stifel 2016 Healthcare And Jefferies 2016 Global Healthcare... Nov 08 2016
7 Analyst Stocks Under $10 for Massive Upside Projections Nov 06 2016
Top Analyst Upgrades and Downgrades: Agrium, Array BioPharma, Encana, GoPro, 3D Systems and More Nov 04 2016
ARRAY BIOPHARMA INC Files SEC form 10-Q, Quarterly Report Nov 03 2016
Edited Transcript of ARRY earnings conference call or presentation 1-Nov-16 1:00pm GMT Nov 01 2016
Array Biopharma Inc Earnings Call scheduled for 9:00 am ET today Nov 01 2016
Array BioPharma reports 1Q loss Nov 01 2016
Array BioPharma reports 1Q loss Nov 01 2016
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2017 Nov 01 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 01 2016
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2017 Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)